{
    "nct_id": "NCT03703492",
    "official_title": "Positron Emission Tomography/Magnetic Resonance Imaging of Estrogen Receptor Expression n Non-Invasive Breast Cancer",
    "inclusion_criteria": "* Diagnosis of biopsy-proven DCIS without invasion or microinvasion measuring at least 1.0 cm in diameter by any imaging modality\n* Undergoing diagnostic breast MRI ordered by the referring clinician for staging and extent of disease\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability or unwillingness to provide informed consent to the study\n* Surgery, radiation, neoadjuvant chemo/endocrine therapy for the current malignancy prior to study enrollment\n* Participants currently taking or have taken an ER-blocking medication (e.g. tamoxifen, raloxifene) within 6 weeks prior to study enrollment\n* Pregnant or lactating women\n* Participant with intolerance or contraindications for MRI or gadolinium-based contrast agents\n* Participant girth exceeds the bore of the MRI/PET scanner\n* Participants with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES\n* Participants in liver failure as judged by the patient's physician, due to the hepatobiliary clearance of 18F-FES\n* Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:\n\n  * The participant has their own prescription for the medication\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver or an alternative plan for transportation (e.g. Uber, taxi, etc.)",
    "miscellaneous_criteria": ""
}